- Home
- NCTY vs CRDL Comparison
NCTY vs CRDL Comparison
Compare NCTY & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- CRDL
- Stock Information
- Founded
- NCTY 1999
- CRDL 2017
- Country
- NCTY China
- CRDL Canada
- Employees
- NCTY N/A
- CRDL N/A
- Industry
- NCTY Business Services
- CRDL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCTY Consumer Discretionary
- CRDL Health Care
- Exchange
- NCTY Nasdaq
- CRDL Nasdaq
- Market Cap
- NCTY 121.2M
- CRDL 126.5M
- IPO Year
- NCTY 2004
- CRDL N/A
- Fundamental
- Price
- NCTY $10.32
- CRDL $1.05
- Analyst Decision
- NCTY
- CRDL Strong Buy
- Analyst Count
- NCTY 0
- CRDL 2
- Target Price
- NCTY N/A
- CRDL $9.00
- AVG Volume (30 Days)
- NCTY 48.4K
- CRDL 1.2M
- Earning Date
- NCTY 01-01-0001
- CRDL 08-14-2025
- Dividend Yield
- NCTY N/A
- CRDL N/A
- EPS Growth
- NCTY N/A
- CRDL N/A
- EPS
- NCTY N/A
- CRDL N/A
- Revenue
- NCTY $15,305,175.00
- CRDL N/A
- Revenue This Year
- NCTY N/A
- CRDL N/A
- Revenue Next Year
- NCTY N/A
- CRDL N/A
- P/E Ratio
- NCTY N/A
- CRDL N/A
- Revenue Growth
- NCTY N/A
- CRDL N/A
- 52 Week Low
- NCTY $6.28
- CRDL $0.77
- 52 Week High
- NCTY $20.59
- CRDL $2.63
- Technical
- Relative Strength Index (RSI)
- NCTY 64.22
- CRDL 39.49
- Support Level
- NCTY $8.60
- CRDL $1.12
- Resistance Level
- NCTY $9.39
- CRDL $1.14
- Average True Range (ATR)
- NCTY 0.67
- CRDL 0.07
- MACD
- NCTY 0.22
- CRDL -0.00
- Stochastic Oscillator
- NCTY 85.53
- CRDL 5.56
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.